First-Line Administration of Fibrinogen Concentrate in the Bleeding Trauma Patient: Searching for Effective Dosages and Optimal Post-Treatment Levels Limiting Massive Transfusion-Further Results of the RETIC Study.

Fibrinogen supplementation is recommended for treatment of severe trauma hemorrhage. However, required dosages and aimed for post-treatment fibrinogen levels remain a matter of discussion. Within the published RETIC study, adult patients suffering trauma-induced coagulopathy were randomly assigned to receive fibrinogen concentrate (FC) as first-line (

Déclaration de conflit d'intérêts

PI has received personal fees from Baxter GmbH, personal fees from CSL Behring GmbH, personal fees from Fresenius Kabi GmbH Austria, personal fees from Bayer GmbH Austria, personal fees from LFB, non-financial support from TEM International, outside the submitted work. DF has received study funding, honoraria for consultancy and board activity from Astra Zeneca, AOP orphan, Baxter, Bayer, BBraun, Biotest, CSL Behring, Delta Select, Dade Behring, Edwards, Fresenius, Glaxo, Haemoscope, Hemogem, Lilly, LFB, Mitsubishi Pharma, NovoNordisk, Octapharm, Pfizer, Tem-Innovation, outside the submitted work. MM has received personal fees from CSL Behring GmbH, outside the submitted work. The remaining authors have disclosed that they have no potential conflicts of interest.